Abstract：
Gliomas are the most frequent primary brain tumour. The proximity of organs at risk, the infiltrating nature, and the radioresistance of gliomas have to be taken into account in the choice of prescribed dose and technique of radiotherapy. The management of glioma patients is based on clinical factors (age, KPS) and tumour characteristics (histology, molecular biology, tumour location), and strongly depends on available and associated treatments, such as surgery, radiation therapy, and chemotherapy. The knowledge of molecular biomarkers is currently essential, they are increasingly evolving as additional factors that facilitate diagnostics and therapeutic decision-making. We present the update of the recommendations of the French society for radiation oncology on the indications and the technical procedures for performing radiation therapy in patients with gliomas.
摘要：
胶质瘤是最常见的原发性脑肿瘤。处于危险中的器官的接近程度，渗透的自然，在选择处方剂量和放射治疗技术时，必须考虑胶质瘤的放射抗性。胶质瘤患者的管理基于临床因素(年龄，KPS)和肿瘤特征(组织学，分子生物学,肿瘤位置)，并且强烈依赖于可用的和相关的治疗方法，比如手术，放射治疗,和化疗。分子生物标志物的知识是目前必不可少的，它们作为促进诊断和治疗决策的额外因素正在不断演变.我们介绍了法国放射肿瘤学会关于神经胶质瘤患者进行放射治疗的适应症和技术程序的最新建议。
